NCT00108186撤回1 期
Celecoxib-Mediated Inhibition of T Regulatory Cells in Human Lung Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Measure bio-markers; safety measures
研究概览
简要总结
This proposal evaluates cyclooxygenase 2 (COX-2) inhibition as a means to decrease T regulatory cell activities and thus augment immune responses against lung cancer. The broad goal focuses on understanding how COX-2 expression regulates the malignant phenotype in non small cell lung cancer in an effort to foster an informed approach for the use of COX-2 inhibitors in prevention and therapy for lung cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically confirmed and surgically resectable non small cell lung cancer and subjects must be ineligible for or refuse, neoadjuvant therapy
排除标准
- •Hypersensitivity to celecoxib or NSAIDs, previous history of GI bleeding or ulceration, chronic or concurrent use of steroids and renal insufficiency
研究组 & 干预措施
Arm 1
Other
Celecoxib is an FDA approved drug for other indications such as osteoarthritis. It is not FDA approved for non-small cell lung cancer.
干预措施: Celecoxib (Drug)
结局指标
主要结局
Measure bio-markers; safety measures
时间窗: 2 years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
4 期
Low-dose IL-2 for Treg Expansion and Tolerance (LITE)TransplantationLiver DiseasesNCT02949492King's College London6
终止
2 期
Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell LymphomaLymphomaNCT00070291Eastern Cooperative Oncology Group4
已完成
1 期
Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerLung CancerNCT00104767Jonsson Comprehensive Cancer Center7
Unknown
3 期
Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving ChemotherapyNon-Small Cell Lung CancerNCT00300729University Hospital, Linkoeping319
终止
2 期
Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung CancerLung CancerNCT00520845Vanderbilt-Ingram Cancer Center23